Education

Ph.D. in Human Retrovirology, Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, 2003

Current position

He is a Research Associate in Department of Genetics, Stanford University School of Medicine. His research focuses on the profiling of novel protein-metabolite interaction for antiviral & anticancer therapeutics development.

Publications

1. Li, X.*, Wang, X.* and Snyder, M. (2013). Systematic investigation of protein-small molecule interactions. IUBMB Life 65(1): 2-8. (*These authors made equal contributions to the work)
2. Wang, X., Tanaka, H., Baba, M. and Cheng, Y.-C. (2009). Study of the retention of metabolites of 4′-Ed4T, a novel anti-HIV-1 thymidine analog, in cells. Antiviral Research 82(2): A27.
3. Wang, X., Uto, T., Akagi, T., Akashi, M. and Baba, M. (2008). Induction of Potent and Specific Humoral and Cellular Immune Responses by Poly(γ-Glutamic Acid) Nanoparticles as an Efficient Antigen Delivery System and Adjuvant. J Med Virol 80: 11-19.
4. Wang, X., Akagi, T., Akashi, M. and Baba, M. (2007). Development of core-corona type polymeric nanoparticles as an anti-HIV-1 vaccine. Mini-Reviews in Organic Chemistry 4(1): 51-59.
5. Wang, X., Uto, T., Akagi, T., Akashi, M. and Baba, M. (2007). Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J Virol 81(18): 10009-10016.
   
6. Wang, X. and Baba, M. (2005). The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother 16(4): 213-216.
7. Wang, X., Uto, T., Sato, K., Ide, K., Akagi, T., Okamoto, M., Kaneko, T., Akashi, M. and Baba, M. (2005). Potent activation of antigen-specific T cells by antigen-loaded nanospheres. Immunol Lett 98(1): 123-130.
   
8. Wang, X., Nitanda, T., Shi, M., Okamoto, M., Furukawa, T., Sugimoto, Y., Akiyama, S. and Baba, M. (2004). Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol 68(7): 1363-1370.
9. Wang, X., Furukawa, T., Nitanda, T., Okamoto, M., Sugimoto, Y., Akiyama, S. and Baba, M. (2003). Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63(1): 65-72.
10. Wang, X., Miyake, H., Okamoto, M., Saito, M., Fujisawa, J.-I., Tanaka, Y., Izumo, S. and Baba, M. (2002). Inhibition of the tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinolone derivative K-37. Molecular pharmacology 61(6): 1359-1365.